# Fosrolapitant and Palonosetron for the Prevention of Antibody-drug Conjugate-induced Nausea and Vomiting

> **NCT07692451** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 124 (estimated)

## Conditions studied

- Nausea and Vomiting Induced by Antibody-drug Conjugates (ADCs)

## Interventions

- **DRUG:** Fosrolapitant and Palonosetron for injection

## Key facts

- **NCT ID:** NCT07692451
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2027-07-15
- **Final completion:** 2027-09-30
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07692451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07692451, "Fosrolapitant and Palonosetron for the Prevention of Antibody-drug Conjugate-induced Nausea and Vomiting". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07692451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*